Federal Awards

Abrams, John, NIH, Suppression of Mobile Elements by p53 Genes, $319,704; Ahmad, Zahid, NIH, Molecular Basis of Autosomal Dominant Hypercholesterolemia in a Multiethnic Cohort, $186,814; Bezprozvanny, Ilya, NIH, Presenilins and Neuronal Calcium Dyshomeostasis, $459,113; Brown, Sherwood, NIH, Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders, $667,050; Burgess, Shawn, NIH, Factors Controlling Metabolic Flux in Liver by NMR Isotopomer Analysis, $34,483; Burma, Sandeep, NIH, Mechanisms of EXO1 Regulation in Response to Radiation-Induced DNA Damage, $320,430; Carroll, Thomas, NIH, UTSW Summer Undergraduate Research Institute for the Study of Kidney Diseases, $100,764;

Cobb, Melanie, NIH, Insulin-Regulated MAP Kinase Pathways, $497,201; Deberardinis, Ralph, NIH, Metabolic Regulators of Tumor Cell Growth, $384,354; Fu, Yang-Xin, NIH, The Role of Id2 in Gut Innate Lymphoid Cells, $352,079; Garg, Abhimanyu, US FDA, Phase 2 Study of Orlistat and SLX-4090 for Type I Hyperlipoproteinemia, $366,719; Gattineni, Jyothsna, NIH, GAT FGF23 and Vascular Calcification, $80,750; Ghose, Subroto, NIH, Synaptic Plasticity in Adolescent Cannabis Users: Relevance to Schizophrenia, $388,327; Glass, Donald, NIH, Investigating the Causes of Keloid Formation, $166,320;

Goldstein, Joseph, NIH, Molecular Basis of Cholesterol Metabolism, $4,282,945; Goodman, Joel, NIH, Simple Cellular Model for Lipodystrophy, $318,000; Green, Carla, NIH, Circadian Regulation of Mitochondrial RNA Polyadenylation, $306,075; Hendrixson, David, NIH, Signal Transduction Pathways for Flagellar Gene Expression in Polar Flagellates, $202,396; Hill, Joseph, NIH, STIM1: Master Regulator of Calcium Homeostasis in Cardiomyocytes, $397,500; Hsiang, Michelle, NIH, Evaluating Re-active Surveillance Strategies for Malaria Elimination, $131,490; Hsieh, Jenny, NIH, Novel Mechanisms of Adult Neurogenesis in Physiological and Pathological Contexts, $129,168;

Huber, Kimberly, NIH, Role of MEF2 and Neural Activity in Cortical Synaptic Weakening and Elimination, $394,331; Jain, Mamta, Mass Gen Hosp/NIH, Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE, $41,779; Jia, Xun, NIH, Explore Random Sampling for Dose Reduction and Scatter Removal in Cone Beam CT, $222,745; Jiang, Jin, NIH, Cell Signaling in Development and Regeneration, $443,634; Johnson, Jane, NIH, Regulation and Function of Asc11 in Neural Development, $347,813; Kapadia, Vishal, NIH, Low versus High Transitional Oxygen Saturation Targets for Preterm Resuscitation, $132,300; Konopka, Genevieve, NIH, The Role of Foxp1-Regulated Signaling Pathways in Brain Development and Behavior, $405,000;

Kraus, Lee, NIH, Role of PARP-1 in Hormone-Related Transcription, $411,774; Lee, Simon, NIH, Care Coordination for Complex Cancer Survivors in an Integrated Safety-Net System, $523,019; Levine, Benjamin, NIH, Aging, Fitness & Failure: Mechanisms of Diastolic Dysfunction, $536,251; Mangelsdorf, David, Univ of Pennsylvania/NIH, Mechanisms and Treatment of Chronic, Latent Human Strongyloidiasis, $127,087; Marrero, Jorge, Georgetown Univ/NIH, Glycans in Hepatocellular Carcinoma, $34,650; Minei, Joseph, Univ of Colorado/Dept of Defense, Sigh Ventilation to Reduce the Incidence and/or the Severity of the Acute Respiratory Distress Syndrome, $69,361; Niederkorn, Jerry, NIH, Immunological Modulation of Ocular Tumor Metastases, $28,218;

Pascual, Juan, NIH, Modulation of Neural Function in Energy Failure, $347,813; Patel, Vishal, NIH, MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease, $364,031; Rizo-Rey, Jose, NIH, Neurotransmitter Release Machinery: Structure and Function, $459,491; Rodan, Aylin, NIH, Probing Intracellular Cl- in a WNK Signaling-Dependent Transporting Epithelium, $81,000; Roth, Michael, NIH, Lung Cancer Oncogenotype-Selective Drug Target Discovery (MPI), $706,409;

Scherer, Philipp, NIH, White Adipose Tissue Physiology, Mitochondrial Function and Adiponectin, $464,280; Shao, Yiping, NIH, Road of PET Image-Based On-line Proton Beam Range Measurement, $139,200; Shaul, Philip, NIH, Fc Gramma RIIB and Inflammation-Related Vascular Disease, $357,750; Skapek, Stephen, Children’s Hosp Philadelphia/NIH, Skapek - NIH NCTN Scientific Leadership - 03, $127,087; Slone, Tamra, Children’s Hosp Philadelphia/NIH, Slone BIQSFP-COG AALL1131 Supplemental Funds, $12,844; Takahashi, Joseph, NIH, Transcriptional Architecture and Chromatin Landscape of Circadian Clocks in Aging Tissue (MPI), $278,250; Timaran, Carlos, Univ of Med and Den of NJ/NIH, Carotid Revascularization Endarterectomy vs. Stent Trial (CREST), $73,263;

Toto, Robert, NIH, UT Southwestern Center for Translational Medicine – UL1, $5,355,813; Toto, Robert, NIH, UT Southwestern Center for Translational Medicine – KL2, $693,945; Toto, Robert, NIH, UT Southwestern Center for Translational Medicine – TL1, $110,253; Trivedi, Madhukar, NIH, Clinical Trials Network: The Texas Node, $785,992;

Word, Ann, NIH, Mechanisms of Prostaglandin-Induced Cervical Ripening in Humans, $332,617; Wu, Jiang, NIH, Role of Brg1 in Activity-Induced Neuronal Gene Expression and Synaptic Plasticity, $365,696; Yan, Nan, Washington Univ St. Louis/CLAYCO Fdn, Molecular Mechanism of RVCL Disease, $180,000.

Non-Federal Awards

Amatruda, James (Fellow K. Chen), Alex’s Lemonade Stand, The Role of miRNA Impairment in Wilms Tumor Formation, $50,000; Goodman, Joel, Texas Workforce Commission, Leagues: Lab Experiments as a Gateway to Understanding & Engaging in Science, $49,770; Henkemeyer, Mark, BrightFocus Fdn, EphB Receptors: Novel Pro-Synaptic Therapeutic Targets for Alzheimer’s Disease, $100,000; Kim, Roy, Jaeb Center for Health/Novo Nordisk, Pediatric Diabetes Consortium Type 2 Diabetes Registry, $720; Malloy, Craig, UTHSC San Antonio/UT System, Transformative MRI_UTD Brain Subcontract, $33,000; Minshall, Christian (Fellow J. Perumean), Texas Higher Educ Coord Bd, Surgical Critical Care Fellowship at UT Southwestern Medical Center, $59,105;

Minter, Rebecca, Univ of Michigan/Josiah Macy Fdn, A New Model for Clinical Education and Progressive Entrustment of Residents, $40,920; Morrison, Sean (Fellow E. Jeffery), Damon Runyon Cancer Res Fdn, Characterizing a New Hematopoietic Stem Cell Niche Factor, $52,000; Nijhawan, Deepak, Damon Runyon Cancer Res Fdn, Developing the Anti-Tumor Toxin CD437 into a New Cancer Therapy, $150,000; Nijhawan, Deepak, Welch Fdn, Expanding the Druggable Genome, $65,000; Olson, Eric (Fellow D. Anderson), Muscular Dystrophy Assoc, Mitigating Muscular Dystrophy with a Calcium-Regulatory Micropeptide, $60,000; Pfeiffer, Brad, Alfred P. Sloan Fdn, Investigations into Circuit-Level Mechanisms of Brain Function, $27,500; Quiceno, Mary, Univ of S Calif/Eli Lilly, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study), $20,750;

Shaul, Philip (Fellow L. Huang), Amer Heart Assoc SW, Endothelial Cell SR-BI and Atherosclerosis, $48,600; Sun, Xiankai, Texas Health Presbyt/Rainwater Charit Fdn, Development of Human Tau Imaging Capability for PSP Research in North Texas, $209,349; Tamminga, Carol, Fdn Assoc/Simons Fdn, Node for Autism BrainNet - FY 16, $217,154; Zhong, Qing, Welch Fdn, Regulation of The Class III P13K by Nutrient-Sensing Kinases in Autophagy, $60,000.

Industry Sponsored Awards, dollar amounts not available

Beg, Muhammad, Phase 2 Study of CF102 for Advanced Hepatocellular Carcinoma for Child-Pugh Class B Cirrhosis, CAN-FITE Biopharma; Blomkalns, Andra, International Collaborative of NT-proBNP Re-evaluation, Harvard Clin Res Inst/Roche; Carr, Bruce, Phase 3 Study of Elagolix with Estradiol/Norethindrone Acetate for Heavy Menstrual Bleeding, ABBVIE; Haley, Barbara, Phase 3 Study of Margetuximab Plus Chemo vs. Trastuzumab Plus Chemo for HER2+ Metastatic Breast Cancer, Parexel/Macrogenics; Jain, Mamta, Phase 3b Study of Ledipasvir/Sofosbuvir for HIV Infected Sbjs Who Switch to E/C/F/TAF or F/R/TAF Treatment, Gilead Sciences; Lee, William, Phase 3b Study of Ledipasvir/Sofosbuvir for HIV Infected Sbjs Who Failed Treatment with Sofosbuvir-Based Therapies, Gilead Sciences; Monson, Nancy, Impact of TG1101 and TGR1202 on EAE, TG Therapeutics; Pan, Edward, Study of Immunotherapy in Newly Diagnosed Glioblastoma, Novella Clin/Immunocellular;

Powell, Craig, Biomarkers Associated with Phelan-McDermid (22q13) Syndrome, Novartis; Rambally, Siayareh, Phase 2 Study of 2 Dose Levels of Imetelstat for Intermediate-2 or High-Risk Myelofibrosis Prev. Treated with Janus Kinase Inhibitor, Janssen; Sawant, Amit, Multimodality Patient-Specific Motion Models, Vision RT; Sumpter, Kathryn, Validation of Two Measures for Growth Hormone Deficiency, Brod Group/Novo Nordisk; Vusirikala, Madhuri, Phase 2 Study of Rituxumab and Bendamustine for Cd30-Positive Diffuse Large B-Cell Lymphoma, PRA Health Sci/Seattle Genetics; Vusirikala, Madhuri, Phase 2 Study of Pembrolizumab (MK-3475) for Primary Mediastinal Large B-Cell Lymphoma, DrugDev/Merck Sharp & Dohme; Vusirikala, Madhuri, Phase 2 Study of SGN-CD19A (19A+RICE) Chemotherapy vs. RICE for Diffuse Large B-cell Lymphoma, Seattle Genetics.